Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China

Zhang X, Zhang H, Li LF, Feng L, Liu Q

Risk Management and Healthcare Policy 2023, 16:1849-1857

Published Date: 12 September 2023